The P2X7 receptor in leukemia: pathological mechanisms and therapeutic potential
- 22 August 2025
- journal article
- review article
- Published by Springer Nature in Purinergic Signalling
- Vol. 21 (6) , 1249-1260
Abstract
The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2023MH307andZR2021MH306)
- Natural Science Foundation of Shandong Province (ZR2023MH307andZR2021MH306)
- National Natural Science Foundation of China (81770915 and 81301737)
This publication has 100 references indexed in Scilit:
- C‐terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis – evidence from clinical and pre‐clinical dataCancer Communications, 2022
- Administration of P2X7 Receptor Blockers in Oncological Experimental Models2022
- Highly‐expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β‐catenin and mTOR/HIF1α/VEGF signalingInternational Journal of Cancer, 2019
- The P2X7 Receptor2017
- P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cellsPurinergic Signalling, 2012
- C terminus of the P2X7 receptor: treasure huntingPurinergic Signalling, 2011
- Identification and characterization of a novel variant of the human P2X7 receptor resulting in gain of functionPurinergic Signalling, 2009
- Purine and pyrimidine receptorsCellular and Molecular Life Sciences, 2007
- Detection of P2X purinergic receptors on human B lymphocytesCell and tissue research, 2001
- Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphomaInternational Journal of Cancer, 1977